UB Paderborn / Katalog / Suche / in CDI

1 – 12 von 12

Sortiert nach

Randomization by minimization for unbalanced treatment allocation

Statistics in medicine, 2009-11, Vol.28 (27), p.3329-3346

2009

Volltextzugriff (PDF)

Models for change in tumour size, appearance of new lesions and survival probability in patients with advanced epithelial ovarian cancer

British journal of clinical pharmacology, 2016-09, Vol.82 (3), p.717-727

2016

Volltextzugriff (PDF)

Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity FcγRIIIa Patients with Previously Treated Follicular Lymphoma

Leukemia & lymphoma, 2015-01, Vol.56 (1), p.42-48

2015

Volltextzugriff (PDF)

Randomized phase II studies and their ethics

Journal of clinical oncology, 2005-12, Vol.23 (36), p.9443-9443

2005

Volltextzugriff (PDF)

An Investigational new drug treatment program for patients with gemcitabine : Results for over 3000 patients with pancreatic carcinoma

Cancer, 1999-03, Vol.85 (6), p.1261-1268

1999

Volltextzugriff (PDF)

Baseline Comparability in Clinical Trials: Prevention of “Poststudy Anxiety”

Therapeutic innovation & regulatory science, 1990-07, Vol.24 (3), p.541-548

1990

Volltextzugriff (PDF)

Nizatidine prevents peptic ulceration in high-risk patients taking nonsteroidal anti-inflammatory drugs

Archives of internal medicine (1960), 1993-11, Vol.153 (21), p.2449

1993

Volltextzugriff (PDF)

An investigational new drug treatment program for patients with gemcitabine

Cancer, 1999-03, Vol.85 (6), p.1261-1268

1999

Volltextzugriff (PDF)

Sensitivity and specificity of tests: Can the “silent majority” speak?

The American journal of cardiology, 1987-11, Vol.60 (14), p.1167-1169

1987

Volltextzugriff (PDF)

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Protein Kinase C β-Inhibitor Enzastaurin in Combination with Gemcitabine and Cisplatin in Patients with Advanced Cancer

Clinical cancer research, 2007-08, Vol.13 (15), p.4474-4481

2007

Volltextzugriff (PDF)

Abstract LB-70: Preliminary results of a Phase I study of AME-133v, an Fc-engineered humanized monoclonal antibody, in low-affinity FcγRIIIa patients with previously-treated follicular lymphoma

Cancer research (Chicago, Ill.), 2008-05, Vol.68 (9_Supplement), p.LB-70-LB-70

2008

Volltextzugriff (PDF)

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Protein Kinase C {szligbeta}-Inhibitor Enzastaurin in Combination with Gemcitabine and Cisplatin in Patients with Advanced Cancer

Clinical cancer research, 2007-08, Vol.13 (15), p.4474-4481

2007

Volltextzugriff (PDF)

1 – 12 von 12

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(11)
Mit Volltextzugriff
(9)

Publikationsform

Artikel
(12)

Sprache

Englisch
(12)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(8)
Life Sciences & Biomedicine
(7)
Science & Technology
(7)
Female
(5)
Male
(5)
Aged
(4)
Middle Aged
(4)
Oncology
(4)
Adult
(3)
Biological And Medical Sciences
(3)
Deoxycytidine - Analogs & Derivatives
(3)
Gemcitabine
(3)
Medical Sciences
(3)
Pharmacology. Drug Treatments
(3)
Antineoplastic Agents
(2)
Clinical Benefit
(2)
Clinical Trials
(2)
Deoxycytidine - Therapeutic Use
(2)
Pain
(2)
Pancreatic Carcinoma
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Randomization by minimization for unbalanced treatment allocation

Models for change in tumour size, appearance of new lesions and survival probability in patients with advanced epithelial ovarian cancer

Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity FcγRIIIa Patients with Previously Treated Follicular Lymphoma

Randomized phase II studies and their ethics

An Investigational new drug treatment program for patients with gemcitabine : Results for over 3000 patients with pancreatic carcinoma

Baseline Comparability in Clinical Trials: Prevention of “Poststudy Anxiety”

Nizatidine prevents peptic ulceration in high-risk patients taking nonsteroidal anti-inflammatory drugs

An investigational new drug treatment program for patients with gemcitabine

Sensitivity and specificity of tests: Can the “silent majority” speak?

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Protein Kinase C β-Inhibitor Enzastaurin in Combination with Gemcitabine and Cisplatin in Patients with Advanced Cancer

Abstract LB-70: Preliminary results of a Phase I study of AME-133v, an Fc-engineered humanized monoclonal antibody, in low-affinity FcγRIIIa patients with previously-treated follicular lymphoma

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Protein Kinase C {szligbeta}-Inhibitor Enzastaurin in Combination with Gemcitabine and Cisplatin in Patients with Advanced Cancer

Suchergebnisse filtern